236 results on '"Balleari, E."'
Search Results
2. Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes
3. P144 - Topic: AS09-Quality of life-Disease experiences: EXPLORING UNMET NEEDS OF MDS PATIENTS AND CAREGIVERS IN A NATIONAL ITALIAN SURVEY
4. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story
5. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome
6. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma
7. Accuracy in suspicious lung infiltrations
8. Impaired in vitro growth of peripheral blood hematopoietic progenitor cells in HIV-infected patients: Evidence of an inhibitory effect of autologous T lymphocytes
9. Gender-related Analysis of Thrombopoietic Cytokine Pattern in Patients with Immune Thrombocytopenic Purpura
10. THERAPY WITH RECOMBINANT ERYTHROPOIETIN IN PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA
11. Different Repo Doses (High vs Standard) for Treatment of Anemia in MDS Patients: A Survey from the Italian MDS Registry
12. MDS-Can-It: A New Validated International ESA-Response Score that Further Refines the Predictive Power of the Nordic Scoring System
13. A Real-Life Study of Deferasirox in Patients with Higher Risk Myelodysplastic Syndromes
14. Effects of Erythropoiesis-Stimulating Agents on Overall Survival of IPSS Low/INT-1 Risk Transfusion Independent Myelodysplastic Syndrome Patients, a FISM Study
15. Outcome of Lower-Risk Patients with Myelodysplastic Syndromes without 5Q Deletion after Failure of Erythropoiesis Stimulating Agents
16. Adult-onset Still's disease associated to toxoplasma gondii infection
17. Anagrelide in Essential Thrombocythemia: a retrospettive study'
18. Androgen metabolism and inhibition of interleukin-1 synthesis in primary cultured human synovial macrophages
19. LENALIDOMIDE IN LOW AND INT-1 RISK MDS: CLINICAL RESULTS OF THE QOL-ESC REVMDS TRIAL
20. HGF-producing mesenchymal stromal cells support chronic lymphocytic leukemic B cells survival
21. Clinically meaningful responses in low risk MDS patients with del5q treated with lenalidomide: Quality of life and cardiac changes
22. Does 18F-fluorodeoxyglucose PET/CT have a role in the management of pulmonary and extra pulmonary sarcoidosis?
23. 147 IN VITRO CULTURE OF BM CELLS AND CYTC POLYMORPHISMS CAN PREDICT THE “IN VIVO” HEMATOLOGICAL RESPONSE INDUCED BY DEFERASIROX
24. 202 BOTH AGE AND COMORBIDITIES NEGATIVELY IMPACT ON CLINICAL OUTCOME OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES: RESULTS FROM A REAL-LIFE REGIONAL SURVEY
25. 301 IRON OVERLOAD AND IRON CHELATION THERAPY WITH DEFERASIROX IN TRANSFUSION-DEPENDENT PATIENTS WITH MYELODYSPLASTIC SYNDROMES
26. Chronic lymphocytic leukemic (CLL) B cells express the HGF receptor (C-MET) and are supported in their survival by HGF-producing mesenchymal stromal cell
27. GENE EXPRESSION PROFILE CHANGES IN BONE MARROW OF MDS PATIENTS WITH DEL5Q DURING LENALIDOMIDE TREATMENT
28. Efficacy, safety feasibility of 5-azacitidine for the treatment of myelodysplastic syndromes in the clinical practice: final results from a retrospective study in177 patients enrolled in the italian patient named program
29. Potent Synergistic Activity of the NAD plus Synthesis Inhibitor APO866 and of the Apoptosis Inducer TRAIL in in Vitro and Ex Vivo Cellular Models of Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
30. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes
31. Effectiveness and safety of combined cytoreductive therapy in 56 patients with essential Thrombocythemia: report of the Regisro Italiano Trombocitemia (RIT)
32. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
33. 5-AZACYTIDINE FOR THE TREATMENT OF INTERMEDIATE-2/HIGH IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 83 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM
34. 284 - A Real-Life Study of Deferasirox in Patients with Higher Risk Myelodysplastic Syndromes
35. 226 - MDS-Can-It: A New Validated International ESA-Response Score that Further Refines the Predictive Power of the Nordic Scoring System
36. 93 - Effects of Erythropoiesis-Stimulating Agents on Overall Survival of IPSS Low/INT-1 Risk Transfusion Independent Myelodysplastic Syndrome Patients, a FISM Study
37. 91 - Different Repo Doses (High vs Standard) for Treatment of Anemia in MDS Patients: A Survey from the Italian MDS Registry
38. 49 - Outcome of Lower-Risk Patients with Myelodysplastic Syndromes without 5Q Deletion after Failure of Erythropoiesis Stimulating Agents
39. Staging and therapy monitoring of multiple myeloma by 99m Tc-sestamibi scintigraphy: a five year single center experience
40. Combination of liposomal Daunorubicin, Fludarabine, and Cytarabine (FLAD) in patients with poor- risk acute leukemia
41. Anagrelide in essential thrombocythemia: a retrospective analysis of 220 patients
42. Anagrelide in assential thronbocythemia: a retrospective study
43. CD 40 triggering enhances fludarabine-induced apoptosisof chronic lymphocytic leukemia B cells through autocrine release of tumor necrosis factor-a and interferon-g and tumor necrosis factor receptor-I-II upregulation
44. Anagrelide treatment in 167 patients with essential thrombocythaemia : a retrospective study of the Italian Group GIMMC
45. Anagrelide treatment in 167 patients with assential thrombocythaemia: a retrospective study of the Italian Group GIMMC
46. Quality of life and brain function during high dose recombinant human erythropoietin treatment in low-risk myelodysplastic syndromes
47. Effect of a new dosing regimen of epoietin alfa on anemia and quality of life in low risk myelodysplastic syndrome patients
48. Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma
49. Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages
50. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.